Literature DB >> 12823080

Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Scott W Woods1.   

Abstract

BACKGROUND: Several clinical and research applications require an estimation of therapeutic dose equivalence across antipsychotic medications. Since the advent of the newer atypical antipsychotics, new dose equivalent estimations have been needed.
METHOD: The reported minimum effective dose was identified for each newer atypical antipsychotic medication and for haloperidol across all available fixed-dose placebo-controlled studies. Reported minimum effective dose equivalence ratios to haloperidol were then converted to chlorpromazine equivalents using the "2 mg of haloperidol equals 100 mg of chlorpromazine" convention. DATA SOURCES AND STUDY SELECTION: To identify the fixed-dose studies, the following sources were searched until June 2002: MEDLINE, the bibliographies of identified reports, published meta-analyses and reviews, Cochrane reviews, Freedom of Information Act material available from the Food and Drug Administration, and abstracts from several scientific meetings from 1997 to 2002.
RESULTS: Doses equivalent to 100 mg/day of chlorpromazine were 2 mg/day for risperidone, 5 mg/day for olanzapine, 75 mg/day for quetiapine, 60 mg/day for ziprasidone, and 7.5 mg/day for aripiprazole.
CONCLUSION: These equivalency estimates may be useful for clinical and research purposes. The source of the dose equivalency estimation is evidence-based and consistent across medication.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12823080     DOI: 10.4088/jcp.v64n0607

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  630 in total

1.  Neuronal generator patterns of olfactory event-related brain potentials in schizophrenia.

Authors:  Jürgen Kayser; Craig E Tenke; Dolores Malaspina; Christopher J Kroppmann; Jennifer D Schaller; Andrew Deptula; Nathan A Gates; Jill M Harkavy-Friedman; Roberto Gil; Gerard E Bruder
Journal:  Psychophysiology       Date:  2010-11       Impact factor: 4.016

2.  3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.

Authors:  Ruth Condray; George G Dougherty; Matcheri S Keshavan; Ravinder D Reddy; Gretchen L Haas; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk; Jeffrey K Yao
Journal:  Int J Neuropsychopharmacol       Date:  2011-01-28       Impact factor: 5.176

3.  White matter integrity, language, and childhood onset schizophrenia.

Authors:  Kristi Clark; Katherine L Narr; Joseph O'Neill; Jennifer Levitt; Prabha Siddarth; Owen Phillips; Arthur Toga; Rochelle Caplan
Journal:  Schizophr Res       Date:  2012-03-10       Impact factor: 4.939

4.  Prolactin-a biomarker for antipsychotic treatment response?

Authors:  Sri M Agarwal; Naren P Rao; Kapil Jhamnani; Ganesan Venkatasubramanian; Rishikesh V Behere; Shivarama Varambally; Bangalore N Gangadhar
Journal:  Prim Care Companion CNS Disord       Date:  2011

5.  The neuroanatomical correlates of cognitive insight in schizophrenia.

Authors:  Maria Donata Orfei; Fabrizio Piras; Enrica Macci; Carlo Caltagirone; Gianfranco Spalletta
Journal:  Soc Cogn Affect Neurosci       Date:  2012-01-28       Impact factor: 3.436

6.  Event-related potentials and changes of brain rhythm oscillations during working memory activation in patients with first-episode psychosis.

Authors:  Pascal Missonnier; François R Herrmann; Adriano Zanello; Maryse Badan Bâ; Logos Curtis; Diana Canovas; Fabrice Chantraine; Jonas Richiardi; Panteleimon Giannakopoulos; Marco C G Merlo
Journal:  J Psychiatry Neurosci       Date:  2012-02       Impact factor: 6.186

7.  An odor-specific threshold deficit implicates abnormal intracellular cyclic AMP signaling in schizophrenia.

Authors:  Bruce I Turetsky; Paul J Moberg
Journal:  Am J Psychiatry       Date:  2008-12-15       Impact factor: 18.112

8.  Creatine abnormalities in schizophrenia and bipolar disorder.

Authors:  Dost Ongür; Andrew P Prescot; J Eric Jensen; Bruce M Cohen; Perry F Renshaw
Journal:  Psychiatry Res       Date:  2009-02-23       Impact factor: 3.222

9.  Reducing emergency medical service use in patients with chronic psychotic disorders: results from the FAST intervention study.

Authors:  Brent T Mausbach; Veronica Cardenas; Christine L McKibbin; Dilip V Jeste; Thomas L Patterson
Journal:  Behav Res Ther       Date:  2007-10-07

10.  Evidence that altered amygdala activity in schizophrenia is related to clinical state and not genetic risk.

Authors:  Roberta Rasetti; Venkata S Mattay; Lisa M Wiedholz; Bhaskar S Kolachana; Ahmad R Hariri; Joseph H Callicott; Andreas Meyer-Lindenberg; Daniel R Weinberger
Journal:  Am J Psychiatry       Date:  2008-12-15       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.